November 21, 2007 - MIV Therapeutics Inc. will sell all of its shares of SagaX Inc. for $4.0 million plus future royalties on sales of 8.0 percent, allowing MIV to focus on the interventional cardiology space and save $1.0 million plus annually in development costs.
The payments will be made in increments of $1.0 million upon the achievement of various equity financing parameters, which may be met by SagaX over a four-year period from closing.
